BHVN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 16.00%

Insider Buying (Last 12 Months): $6,271,162.00

Insider Selling (Last 12 Months): $0.00

Biohaven Insider Trading History Chart

Biohaven Share Price & Price History

^$19.81

▼ -3.595 (-15.36%)

As of 04/25/2025 04:59 PM ET

Days: 30 | 90 | 365

Biohaven Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2025	John W. Childs	Director	Buy	32,700	$30.47	$996,369.00	2,320,571
12/30/2024	John W. Childs	Director	Buy	29,000	$35.94	$1,042,260.00	2,368,741
10/2/2024	John W. Childs	Director	Buy	21,052	$47.50	$999,970.00	21,052
9/24/2024	Gregory H. Bailey	Director	Buy	5,000	$44.19	$220,950.00	1,620,071
7/18/2024	John W. Childs	Director	Buy	28,400	$35.67	$1,013,028.00	2,339,741
5/30/2024	John W. Childs	Director	Buy	28,000	$35.58	$996,240.00	2,311,341
5/13/2024	John W. Childs	Director	Buy	28,500	$35.17	$1,002,345.00	2,283,341
4/24/2024	Gregory H. Bailey	Director	Buy	25,503	$39.18	$999,207.54	1,600,071
4/22/2024	Gregory H. Bailey	Director	Buy	48,780	$41.00	$1,999,980.00	1,574,568
4/22/2024	Vlad Coric	CEO	Buy	121,951	$41.00	$4,999,991.00	1,788,417
12/29/2023	Irina Antonijevic	Director	Sell	11,000	$41.79	$459,690.00	2,535
10/5/2023	Matthew Buten	CFO	Buy	22,727	$22.00	$499,994.00	189,380
10/5/2023	Vlad Coric	CEO	Buy	113,637	$22.00	$2,500,014.00	1,657,031
10/4/2023	Gregory H. Bailey	Director	Buy	17,817	$22.57	$402,129.69	1,525,788
8/30/2023	John W. Childs	Director	Buy	50,000	$18.44	$922,000.00	1,975,118
8/4/2023	John W. Childs	Director	Buy	100,000	$19.78	$1,978,000.00	1,925,118
10/31/2022	Vlad Coric	CEO	Buy	25,800	$15.97	$412,026.00	1,543,394
10/28/2022	Vlad Coric	CEO	Buy	41,930	$14.87	$623,499.10	1,517,594
10/25/2022	Gregory H. Bailey	Director	Buy	200,000	$10.50	$2,100,000.00	1,507,971
10/25/2022	Matthew Buten	CFO	Buy	142,857	$10.50	$1,499,998.50	166,653
10/25/2022	Vlad Coric	CEO	Buy	853,380	$10.50	$8,960,490.00	1,475,664
8/19/2022	Gregory H. Bailey	Director	Buy	38,000	$148.04	$5,625,520.00	2,583,658
5/10/2022	George C. Clark	CAO	Sell	4,200	$141.50	$594,300.00	4,065

See Full Table

SEC Filings (Institutional Ownership Changes) for Biohaven (NYSE:BHVN)

88.78% of Biohaven stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Biohaven Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/25/2025	Peregrine Capital Management LLC	153,825	$3.70M	0.1%	+3.3%	0.151%
4/25/2025	KBC Group NV	4,560	$0.11M	0.0%	+35.0%	0.004%
4/17/2025	Exchange Traded Concepts LLC	15,569	$0.37M	0.0%	-4.4%	0.015%
4/15/2025	SG Americas Securities LLC	23,029	$0.55M	0.0%	+155.8%	0.023%
4/9/2025	Weybosset Research & Management LLC	16,880	$0.41M	0.1%	+23.7%	0.017%
4/8/2025	Rhumbline Advisers	124,839	$3M	0.0%	+6.2%	0.122%
4/8/2025	Parallel Advisors LLC	1,360	$33K	0.0%	+319.8%	0.001%
4/7/2025	GAMMA Investing LLC	8,558	$0.21M	0.0%	+8,908.4%	0.008%
3/24/2025	Wellington Management Group LLP	634,055	$23.68M	0.0%	+160.7%	0.621%
3/18/2025	California State Teachers Retirement System	74,144	$2.77M	0.0%	+10.4%	0.073%
2/28/2025	Universal Beteiligungs und Servicegesellschaft mbH	12,032	$0.45M	0.0%	N/A	0.012%
2/26/2025	Infinitum Asset Management LLC	110,000	$4.11M	2.2%	N/A	0.109%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	548,575	$20.49M	0.0%	+7.9%	0.542%
2/17/2025	Voloridge Investment Management LLC	100,568	$3.76M	0.0%	-62.2%	0.099%
2/17/2025	Woodline Partners LP	601,922	$22.48M	0.2%	-34.8%	0.595%
2/17/2025	Two Sigma Advisers LP	99,900	$3.73M	0.0%	-45.8%	0.099%
2/17/2025	Two Sigma Investments LP	80,863	$3.02M	0.0%	-71.2%	0.080%
2/17/2025	TrinityPoint Wealth LLC	37,095	$1.39M	0.2%	N/A	0.037%
2/17/2025	Stempoint Capital LP	186,413	$6.96M	1.7%	-13.9%	0.184%
2/17/2025	Suvretta Capital Management LLC	5,620,271	$209.92M	7.2%	+8.1%	5.558%
2/17/2025	Sphera Funds Management LTD.	156,494	$5.85M	1.1%	+17.4%	0.155%
2/17/2025	Rafferty Asset Management LLC	135,256	$5.05M	0.0%	-1.7%	0.134%
2/17/2025	Redmile Group LLC	904,496	$33.78M	2.4%	-12.5%	0.894%
2/17/2025	Point72 Asset Management L.P.	922,965	$34.47M	0.1%	-38.5%	0.913%
2/17/2025	ProShare Advisors LLC	24,189	$0.90M	0.0%	+70.5%	0.024%
2/17/2025	Nicholas Investment Partners LP	18,673	$0.70M	0.1%	-26.6%	0.018%
2/17/2025	Nuveen Asset Management LLC	919,235	$34.33M	0.0%	+55.1%	0.909%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	54,271	$2.02M	0.0%	+32.0%	0.054%
2/17/2025	Lazard Asset Management LLC	3,207	$0.12M	0.0%	+47.4%	0.003%
2/17/2025	Lion Point Capital LP	22,700	$0.85M	4.4%	-35.9%	0.022%
2/17/2025	Janus Henderson Group PLC	6,982,425	$260.74M	0.1%	+12.1%	6.905%
2/17/2025	Farallon Capital Management LLC	4,428,167	$165.39M	0.8%	+21.6%	4.379%
2/17/2025	Fred Alger Management LLC	104,567	$3.91M	0.0%	+79.8%	0.103%
2/17/2025	D. E. Shaw & Co. Inc.	170,647	$6.37M	0.0%	-70.5%	0.169%
2/17/2025	Deutsche Bank AG	169,773	$6.34M	0.0%	+25.0%	0.168%
2/17/2025	DAFNA Capital Management LLC	220,235	$8.23M	2.1%	+17.7%	0.218%
2/17/2025	Cubist Systematic Strategies LLC	23,671	$0.88M	0.0%	N/A	0.023%
2/17/2025	Boone Capital Management LLC	361,420	$13.50M	4.6%	N/A	0.357%
2/17/2025	Brown Advisory Inc.	975,585	$36.44M	0.0%	+0.7%	0.965%
2/17/2025	Bamco Inc. NY	44,000	$1.64M	0.0%	-2.2%	0.044%
2/17/2025	Bank of America Corp DE	310,559	$11.60M	0.0%	+40.5%	0.307%
2/17/2025	BNP Paribas Financial Markets	41,762	$1.56M	0.0%	N/A	0.041%
2/17/2025	Ameriprise Financial Inc.	508,682	$18.99M	0.0%	+40.0%	0.503%
2/17/2025	Algert Global LLC	31,320	$1.17M	0.0%	-3.3%	0.031%
2/17/2025	Alyeska Investment Group L.P.	106,351	$3.97M	0.0%	+129.4%	0.105%
2/14/2025	Bison Wealth LLC	332,428	$12.42M	2.7%	+0.4%	0.329%
2/14/2025	Emerald Mutual Fund Advisers Trust	226,394	$8.46M	0.5%	N/A	0.224%
2/14/2025	Northern Trust Corp	811,155	$30.30M	0.0%	+19.9%	0.802%
2/14/2025	The Manufacturers Life Insurance Company	199,183	$7.44M	0.0%	+3.4%	0.197%
2/14/2025	Quarry LP	3,000	$0.11M	0.0%	N/A	0.003%
2/14/2025	Tri Locum Partners LP	140,220	$5.24M	1.1%	-27.4%	0.139%
2/14/2025	Virtus ETF Advisers LLC	1,770	$66K	0.0%	-35.9%	0.002%
2/14/2025	Voya Investment Management LLC	713,587	$26.65M	0.0%	-0.8%	0.706%
2/14/2025	Adage Capital Partners GP L.L.C.	575,000	$21.48M	0.0%	-61.2%	0.569%
2/14/2025	Hood River Capital Management LLC	783,672	$29.27M	0.4%	-13.2%	0.775%
2/14/2025	Price T Rowe Associates Inc. MD	3,412,191	$127.45M	0.0%	-0.8%	3.374%
2/14/2025	Hsbc Holdings PLC	10,361	$0.38M	0.0%	+10.8%	0.010%
2/14/2025	Rock Springs Capital Management LP	129,858	$4.85M	0.2%	+1.8%	0.128%
2/14/2025	Stifel Financial Corp	6,559,313	$244.99M	0.3%	+0.8%	6.487%
2/14/2025	Tower Research Capital LLC TRC	12,180	$0.46M	0.0%	+2,952.6%	0.012%
2/14/2025	Transatlantique Private Wealth LLC	13,431	$0.50M	0.2%	-5.0%	0.013%
2/14/2025	MYDA Advisors LLC	54,000	$2.02M	0.5%	-22.9%	0.053%
2/14/2025	MetLife Investment Management LLC	51,737	$1.93M	0.0%	+19.0%	0.051%
2/14/2025	Altium Capital Management LLC	250,000	$9.34M	2.6%	+233.3%	0.247%
2/13/2025	Marshall Wace LLP	366,891	$13.70M	0.0%	-1.3%	0.363%
2/13/2025	Gabelli Funds LLC	9,000	$0.34M	0.0%	-31.8%	0.009%
2/13/2025	Elkhorn Partners Limited Partnership	3,300	$0.12M	0.1%	+50.0%	0.003%
2/13/2025	Barclays PLC	392,727	$14.67M	0.0%	+46.5%	0.388%
2/13/2025	Summit Investment Advisors Inc.	8,985	$0.34M	0.3%	+18.1%	0.009%
2/13/2025	Neuberger Berman Group LLC	129,465	$4.84M	0.0%	+2,953.4%	0.128%
2/13/2025	Capital Fund Management S.A.	38,488	$1.44M	0.0%	+130.1%	0.038%
2/13/2025	F M Investments LLC	26,338	$0.98M	0.0%	N/A	0.026%
2/13/2025	Raymond James Financial Inc.	37,033	$1.38M	0.0%	N/A	0.037%
2/13/2025	Renaissance Technologies LLC	19,352	$0.72M	0.0%	N/A	0.019%
2/13/2025	FIL Ltd	89,391	$3.34M	0.0%	+4.9%	0.088%
2/13/2025	Legal & General Group Plc	90,847	$3.39M	0.0%	+5.1%	0.090%
2/13/2025	Invesco Ltd.	51,814	$1.94M	0.0%	+6.2%	0.051%
2/13/2025	Federated Hermes Inc.	12,753	$0.48M	0.0%	-41.0%	0.013%
2/13/2025	Russell Investments Group Ltd.	146,125	$5.46M	0.0%	-10.3%	0.145%
2/13/2025	Wells Fargo & Company MN	43,650	$1.63M	0.0%	+30.6%	0.043%
2/12/2025	Landscape Capital Management L.L.C.	18,710	$0.70M	0.1%	N/A	0.019%
2/12/2025	Bryce Point Capital LLC	32,000	$1.20M	0.3%	N/A	0.032%
2/12/2025	Trexquant Investment LP	10,980	$0.41M	0.0%	-41.5%	0.011%
2/12/2025	Geode Capital Management LLC	1,905,366	$71.18M	0.0%	+11.1%	1.884%
2/12/2025	Franklin Resources Inc.	74,300	$2.78M	0.0%	-6.8%	0.073%
2/12/2025	Alliancebernstein L.P.	96,236	$3.59M	0.0%	+6.6%	0.095%
2/12/2025	Wellington Management Group LLP	634,055	$23.68M	0.0%	+160.7%	0.627%
2/12/2025	O Shaughnessy Asset Management LLC	9,777	$0.37M	0.0%	-2.7%	0.010%
2/12/2025	Clearbridge Investments LLC	521,099	$19.46M	0.0%	+8.7%	0.515%
2/12/2025	CIBC Private Wealth Group LLC	790	$31K	0.0%	-39.5%	0.001%
2/12/2025	RWA Wealth Partners LLC	11,800	$0.44M	0.0%	+81.5%	0.012%
2/12/2025	DnB Asset Management AS	7,526	$0.28M	0.0%	+8.2%	0.007%
2/12/2025	Pictet Asset Management Holding SA	405,848	$15.16M	0.0%	+32.2%	0.401%
2/12/2025	Norges Bank	902,565	$33.71M	0.0%	N/A	0.893%
2/12/2025	JPMorgan Chase & Co.	1,979,169	$73.92M	0.0%	+144.5%	1.957%
2/11/2025	EFG Asset Management North America Corp.	56,713	$2.12M	0.3%	N/A	0.056%
2/11/2025	Prudential Financial Inc.	5,980	$0.22M	0.0%	+9.4%	0.006%
2/11/2025	Corebridge Financial Inc.	42,701	$1.60M	0.0%	+6.4%	0.042%
2/11/2025	Emerald Advisers LLC	360,538	$13.47M	0.5%	N/A	0.357%
2/11/2025	Vanguard Group Inc.	8,414,120	$314.27M	0.0%	+8.1%	8.321%

Data available starting January 2016

See Full Table

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $19.81

$17.42

$23.17

50 Day Range

MA: $26.44

$16.53

$39.77

52 Week Range

Now: $19.81

$15.79

$55.70

Volume

6,163,647 shs

Average Volume

1,130,618 shs

Market Capitalization

$2.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Who are the company insiders with the largest holdings of Biohaven?: Biohaven's top insider shareholders include:
John W Childs (Director)
Vlad Coric (CEO)
Gregory Bailey (Director)
Matthew Buten (CFO)
Irina Antonijevic (Director)
Learn More about top insider investors at Biohaven.
Who are the major institutional investors of Biohaven?: Biohaven's top institutional shareholders include:
Peregrine Capital Management LLC — 0.15%
Rhumbline Advisers — 0.12%
SG Americas Securities LLC — 0.02%
Weybosset Research & Management LLC — 0.02%
Exchange Traded Concepts LLC — 0.02%
GAMMA Investing LLC — 0.01%
Learn More about top institutional investors of Biohaven stock.
Which major investors are selling Biohaven stock?: During the last quarter, BHVN stock was sold by these institutional investors:
Exchange Traded Concepts LLC
Which major investors are buying Biohaven stock?: During the last quarter, BHVN stock was bought by institutional investors including:
SG Americas Securities LLC
GAMMA Investing LLC
Rhumbline Advisers
Peregrine Capital Management LLC
Weybosset Research & Management LLC
KBC Group NV
Parallel Advisors LLC
Within the previous year, these company insiders have bought Biohaven stock:
John W Childs (Director)
Vlad Coric (CEO)
Gregory Bailey (Director)
Matthew Buten (CFO)
Learn More investors buying Biohaven stock.